Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer

Published:2021-12-30 Issue:4 Volume:26 Page:1332-1337
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Keresztes Dávid¹^ORCID,Csizmarik Anita¹,Nagy Nikolett¹,Módos Orsolya¹,Fazekas Tamás¹,Bracht Thilo²³⁴,Sitek Barbara²³⁴,Witzke Kathrin²⁴,Puhr Martin⁵,Sevcenco Sabina⁶,Kramer Gero⁷,Shariat Shahrokh⁷,Küronya Zsófia⁸,Takács László⁹¹⁰,Tornyi Ilona⁹,Lázár József¹⁰,Hadaschik Boris¹¹,Lászik András¹²,Szűcs Miklós¹,Nyirády Péter¹,Szarvas Tibor¹¹¹

Affiliation:

1. Department of Urology Semmelweis University Budapest Hungary

2. Medical Faculty Medizinisches Proteom‐CenterRuhr‐University Bochum Bochum Germany

3. Department of Anesthesia Intensive Care Medicine and Pain Therapy University Hospital Knappschaftskrankenhaus Bochum Bochum Germany

4. Center for Protein Diagnostics Medical Proteome Analysis Ruhr‐University Bochum Bochum Germany

5. Department of Urology Medical University of Innsbruck Innsbruck Austria

6. Department of Urology Donauspital Vienna Austria

7. Department of Urology Medical University of Vienna Vienna Austria

8. Department of Genitourinary Medical Oncology and Clinical Pharmacology National Institute of Oncology Budapest Hungary

9. Department of Human Genetics Faculty of Medicine University of Debrecen Debrecen Hungary

10. Biosystems International Kft. Debrecen Hungary

11. Department of Urology University of Duisburg‐Essen Essen Germany

12. Department of Forensic and Insurance Medicine Semmelweis University Budapest Hungary

Funder

National Research, Development and Innovation Office

Ministry of Innovation, Science, Research and Technology of the State of North Rhine-Westphalia

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.17141

Reference15 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

3. Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cells;Cellular Oncology;2024-08-20

2. Unveiling the characteristics of D4 and R4 aptamers for their future use in prostate cancer clinical practice;Biophysical Chemistry;2024-08

3. Observations of amyloid breakdown by proteases over time using scanning acoustic microscopy;Scientific Reports;2023-11-24

4. Development of a sandwich ELISA to detect circulating, soluble IRAP as a potential disease biomarker;Scientific Reports;2023-11-24

5. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis;Urologic Oncology: Seminars and Original Investigations;2023-04